Newsletter

Subscribe and recieve updates on this company.

Text STOCKS to 72727 for mobile alerts

We are excited to present Vertex Pharmaceuticals Inc. (NASDAQ: VRTX).

Full DD Report for VRTX

You must become a subscriber to view this report.


Recent News from (NASDAQ: VRTX)

Crispr Therapeutics Tries Its Hand At ?-Thalassemia With Vertex
The CRISPR gene editing system has been one of the most fascinating subsectors of biotech ever since the first CRISPR companies went public not long ago. Up until late August though, it was all preclinical and theoretical. But back on August 27th, CRISPR Therapeutics ( CRSP ) and Vertex Pharma...
Source: SeekingAlpha
Date: September, 13 2018 11:21
Vertex to Present at the Morgan Stanley Healthcare Conference on September 14
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that management will present at the Morgan Stanley Healthcare Conference on Friday, September 14, 2018 at 12:15 p.m. ET. The audio portion of management’s remarks will be available live through Vertex’s we...
Source: Business Wire
Date: September, 11 2018 16:01
Vertex Appoints Katharine Jensen as Head of Corporate Social Responsibility
-- Ms. Jensen to oversee global CSR efforts and lead The Vertex Foundation -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced that Katharine Jensen has been appointed Head of Corporate Social Responsibility (CSR). In this role, Ms. Jensen will oversee all aspects of...
Source: Business Wire
Date: September, 10 2018 09:11
Vertex Completes Enrollment of Two Phase 3 Studies of VX-659 in Triple Combination with Tezacaftor and Ivacaftor for the Treatment of Cystic Fibrosis
-Data expected in late 2018 from Phase 3 studies of VX-659, tezacaftor and ivacaftor in people with one F508del mutation and one minimal function mutation and in people with two F508del mutations- -Enrollment of two Phase 3 studies of VX-445 in triple combination with tezacaftor and iv...
Source: Business Wire
Date: September, 06 2018 08:00
Small Caps Are Rising, Biotechs Can't Be Far Behind
Market Pulse The S&P 500 has finally emerged from its 7-month consolidation as it weaves its way back to chalking all-time highs. While that is an event worth acknowledging, it may not be as breathless a milestone when one realizes that the small cap Russell 2000 index led the market and...
Source: SeekingAlpha
Date: September, 05 2018 13:31

 


Last 5 Days Trading Activity

DateOpen PriceClose PriceHighLowVolume
2018-09-14179.37179.86181.11178.005830,409
2017-03-1094.1593.6894.2293.27201,234
2017-03-0992.4593.5793.6091.961,217,095
2017-03-0891.1192.1893.4091.111,763,195
2017-03-0790.1491.3291.7089.771,960,731

Last 5 Days Short Activity

DateShort VolumeTotal VolumeShort PercentageShort Indicator
2018-12-1060,517151,09340.0528Short
2018-12-07146,375319,37845.8313Short
2018-12-0697,289411,41323.6475Cover
2018-12-0488,689275,30232.2152Cover
2018-12-03240,118517,62046.3889Short

* Short Mode

Short Analysis provided by Squeeze Report. Get a complete short report on VRTX.


About Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Logo for Vertex Pharmaceuticals Inc. (NASDAQ: VRTX)

Not available

 

Contact Information

 

 

Current Management

  • Joshua S. Boger / CEO
  • Vicki L. Sato / President
  • Ian F. Smith / CFO

Current Share Structure

  • Market Cap: $40,069,505,680 - 05/18/2018
  • Issue and Outstanding: 254,830,232 - 04/20/2018

 


Recent Filings from (NASDAQ: VRTX)

Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: July, 26 2018
Securities offered to employees under employee benefit plans
Filing Type: S-8Filing Source: edgar
Filing Date: July, 26 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: July, 25 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: May, 18 2018
Notice of exempt solicitation. Definitive material
Filing Type: PX14A6GFiling Source: edgar
Filing Date: May, 07 2018
Quarterly report with a continuing view of a company's financial position
Filing Type: 10-QFiling Source: edgar
Filing Date: April, 27 2018
Report of unscheduled material events or corporate changes.
Filing Type: 8-KFiling Source: edgar
Filing Date: April, 26 2018
Official notification to shareholders of matters to be brought to a vote (Proxy)
Filing Type: DEF 14AFiling Source: edgar
Filing Date: April, 17 2018
Preliminary proxy statement providing notification matters to be brought to a vote
Filing Type: PRE 14AFiling Source: edgar
Filing Date: April, 06 2018
Filing Type: CT ORDERFiling Source: edgar
Filing Date: April, 03 2018

 

 


Daily Technical Chart for (NASDAQ: VRTX)

Daily Technical Chart for (NASDAQ: VRTX)


Stay tuned for daily updates and more on (NASDAQ: VRTX)

It most certainly could but even more important is the recent overwhelming interest in the company. Check out Investors Hub and search on Twitter

More to come on (NASDAQ: VRTX)

Do your DD and if you choose, be ready to go!


 

The Research: All source information contained in this email is from the public sources mentioned below.

 

 
 

Thank you

DD Report
@DDReports

 

 


Disclaimer: DD Report publishes reports providing information on selected companies. DD Report is not a registered investment advisor or broker-dealer. This report is provided as an information service only, and the statements and opinions in this report should not be construed as an offer or solicitation to buy or sell any security. DD Report accepts no liability for any loss arising from an investors reliance on or use of this report. An investment in VRTX is considered to be highly speculative and should not be considered unless a person can afford a complete loss of investment. DD Report has received no compensation for the publication and circulation of this report. DD Report does not own any shares of VRTX and does not buy, sell, or trade any shares of VRTX. This report contains forward-looking statements, which involve risks, and uncertainties that may cause actual results to differ materially from those set forth in the forward-looking statements. Copyright 2018 by DD Report. All rights reserved. Our Full Disclaimer: https://dd.report/disclaimer/